Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology Stock Is Rocketing Higher Today

By George Budwell - Updated Jun 9, 2021 at 11:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This unloved biotech is finding new life on social media.

What happened

Shares of Clovis Oncology (CLVS 2.56%), a commercial-stage biotech, were up by a healthy 15.6% as of 10:27 a.m. EDT Wednesday morning. The biotech's shares are ripping higher today due to the WallStreetBets subreddit crowd.

The main attraction for the WallStreetBets folks appears to be Clovis' sizable short interest. At last count, almost a third of the company's float was sold short, per the Nasdaq stock exchange, making it an intriguing short squeeze candidate.  

A rocket taking off.

Image source: Getty Images.

So what

When retail investors join into a large group, they can certainly force short-sellers to cover their positions. Clovis, however, may have trouble sustaining these sudden gains despite its newfound popularity on social media.

The harsh truth is that the biotech's large short interest definitely has a strong rationale behind it. Namely, Clovis' ovarian cancer drug Rubraca hasn't been able to compete effectively in a jam-packed marketplace since its original approval almost five years ago.

Underscoring this point, the drug raked in a mere $38.1 million in sales during the first quarter of 2021. And as a direct result of Rubraca's poor commercial performance, Clovis has had to repeatedly tap the public markets for capital, which hasn't helped its share price, to say the least.

The graph below illustrates this point nicely:

CLVS Chart

CLVS data by YCharts.

Now what

Is Clovis worth the risk? On the one hand, its shares might be grossly undervalued. Wall Street's current consensus estimate, after all, has Rubraca's sales jumping by a whopping 45% to $254 million in 2022. If true, the biotech's shares would be trading at less than three times next year's sales at current levels. That's an outright bargain in the world of biopharma.

Then again, we've heard this story about this drug before, and so far, Rubraca has failed to live up to expectations. As such, value investors might want to sit this one out for the time being.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
$1.41 (2.56%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.